Objective To explore the curative effect of recombinant human erythropoietin(rHuEPO )on anaemia associated with regular chemotherapy in patients with blood cancer. Methods Eighty leuKemia patients who received regular chemotherapy were selected for the study. Patients in group A were also treated with erythropoietin therapy(47 cases),patients in group B received regular chemotherapy but without eryth-ropoietin therapy(33 cases). Blood hemoglobin level in the peripheral blood was detected in the second and fourth weeK after chemotherapy,and the third weeK after rHuEPO treatment. Hemoglobin level was compared between two groups. Results In group A,the mean hemoglobin level of 4 weeKs of chemotherapy was decreased obviously compared with 2 weeKs of chemotherapy( P < 0. 01)and it was significantly increased after 3 weeKs of rHuEPO treatment compared with that in the fourth weeK chemotherapy( P < 0. 01). In group B,the mean hemoglobin level of 4 weeKs of chemotherapy was obviously decreased compared with 2 weeKs of chemotherapy( P < 0. 01),and it was further decreased at the time corre-sponding to the third weeKs of rHuEPO treatment in group A in comparison with the value of 4 weeKs of chemotherapy( P < 0. 01). Conclusion Anemia caused by chemotherapy in patients with leuKemia can be improved by rHuEPO treatment.%目的：探讨重组人促红细胞生成素（rHuEPO）对白血病患者接受正规化疗相关贫血的疗效。方法筛选80例白血病患者，均接受正规化疗，行 rHuEPO 治疗的患者为 A 组（47例），未行 rHuEPO 治疗的患者为 B 组（33例），治疗观察周期均为3周。检测 A 组患者化疗第2周和化疗第4周以及 rHuEPO 治疗后第3周外周血血红蛋白含量，以及 B组相应时间点外周血血红蛋白含量，分别进行比较。结果 A 组：化疗第4周与化疗第2周相比，外周血平均血红蛋白含量明显降低（ P <0.01）；EPO 治疗后第3周与化疗第4周相比，外周血平均血红蛋白含量明显升高（ P <0.01）。B组：化疗第4周与化疗第2周相比，外周血平均血红蛋白含量明显降低（ P <0.01）；相当于 EPO 治疗后第3周时间与化疗第4周相比，外周血平均血红蛋白含量再一次明显降低（ P <0.01）。结论白血病患者化疗期间所导致的贫血可以给予重组促红细胞生成素来改善，有助于白血病患者稳定病情。
展开▼
